Reported 7 months ago
This article highlights two stocks, Soleno Therapeutics and MoneyLion, which are considered strong buys with significant growth potential based on their strong performance and positive analyst ratings. Soleno has seen an 869% increase over the past year due to promising clinical trials, while MoneyLion has experienced a 635% rise as it expands its fintech services and customer base. Both stocks hold a Strong Buy consensus from analysts.
Source: YAHOO